Nanospectra Biosciences is at the forefront of nanomedicine, focusing on the development of its proprietary AuroLase® Therapy, which utilizes a unique class of nanoparticles known as AuroShells®. These nanoshells are engineered to absorb near-infrared light, which allows them to convert this energy into heat. When administered intravenously, AuroShells accumulate selectively in tumor tissues due to their enhanced permeability and retention in the leaky vasculature of tumors. Upon illumination with a near-infrared laser, the absorbed energy generates localized heat that effectively destroys the tumor and its blood supply while sparing surrounding healthy tissue. This innovative approach aims to provide a safer and more effective alternative to traditional cancer treatments, such as surgery and radiation.

The AuroLase Therapy is particularly notable for its application in prostate cancer treatment, where it is designed to maximize therapeutic efficacy while minimizing side effects. The therapy is currently undergoing pivotal clinical trials, demonstrating promising results in terms of safety and efficacy. Nanospectra's technology platform not only targets solid tumors but also holds potential for broader applications in tissue and drug delivery. By leveraging advanced imaging techniques, such as MRI/ultrasound fusion, clinicians can accurately direct the laser to the tumor site, enhancing the precision of the treatment. Overall, Nanospectra Biosciences is committed to advancing its innovative therapies through ongoing research and strategic partnerships, aiming to fulfill the promise of nanomedicine in oncology.

United States

Nanospectra Biosciences is a medical device company that specializes in nanomedicine for selective thermal ablation, with their lead product aimed at treating prostate cancer tissue.

Nanospectra Biosciences

Company Details